Efficacy of Sodium Glucose Cotransporter 2 Inhibitors on Non-Alcoholic Fatty Liver Disease

ConditionsNon Alcholic Fatty Liver Disease Hepatic Steatosis Hepatic Fibrosis NAFLD (Nonalcoholic Fatty Liver Disease)

Trial statusNot yet recruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age18-65

SponsorAssiut University

About this trial

evaluate the effectiveness of sodium-glucose cotransporter-2 (SGLT.2) inhibitors in improving hepatic steatosis and hepatic fibrosis using imaging biomarkers and histopathology in patients with non-alcoholic fatty liver disease

Eligibility criteria

Qualifiers

age >18 years

both sex

Disqualifiers

alcohol drinker

any cause of liver affection (hepatitis, autoimmune…etc)

patients with kidney function affection

Trial design

Treatments tested in this trial

Not listed

Trial groups

No trial groups listed

Locations

This trial has no locations

Sponsors and collaborators

Assiut University

Lead sponsor

Source ClinicalTrials.gov